BCR / ABL – Complete Molecular Genetic Analysis

Description

**BCR / ABL – Complete Molecular Genetic Analysis**

The BCR / ABL – Complete Molecular Genetic Analysis is a highly specialized diagnostic test designed to detect and quantify the presence of the BCR-ABL fusion gene, a genetic abnormality commonly associated with certain types of leukemia, including chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). This test plays a critical role in diagnosing, monitoring, and managing these conditions, offering valuable insights into disease progression and treatment effectiveness.

### Why You Need This Test
The BCR / ABL – Complete Molecular Genetic Analysis is essential for individuals suspected of having leukemia or those undergoing treatment for CML or ALL. The BCR-ABL fusion gene results from a chromosomal translocation (Philadelphia chromosome) that leads to the production of an abnormal tyrosine kinase protein, driving uncontrolled cell growth. This test provides precise molecular-level data to confirm the presence of this genetic abnormality, assess disease burden, and monitor response to targeted therapies like tyrosine kinase inhibitors (TKIs). Early detection and ongoing monitoring are crucial for effective disease management and improving long-term outcomes.

### Symptoms That Indicate This Test
You may need the BCR / ABL – Complete Molecular Genetic Analysis if you experience symptoms or conditions such as:
– Persistent fatigue or weakness
– Unexplained weight loss
– Night sweats
– Fever without infection
– Easy bruising or bleeding
– Enlarged spleen (felt as abdominal discomfort or fullness)
– High white blood cell counts detected in routine blood tests
– Diagnosis of leukemia requiring molecular confirmation

These symptoms and conditions are often associated with CML, ALL, or other hematologic malignancies linked to the BCR-ABL fusion gene.

### Natural Production
Under normal circumstances, the body does not produce the BCR-ABL fusion gene. This genetic abnormality arises from a translocation between chromosomes 9 and 22, forming the Philadelphia chromosome. The resulting fusion gene produces an abnormal tyrosine kinase protein that disrupts normal cell signaling, leading to uncontrolled cell proliferation. Factors such as genetic predisposition or exposure to certain environmental triggers may increase the risk of developing this abnormality.

### What Happens If Untreated
If left undiagnosed or untreated, the presence of the BCR-ABL fusion gene can lead to the progression of leukemia, causing severe complications such as bone marrow failure, increased susceptibility to infections, and organ damage due to excessive white blood cell production. In advanced stages, the disease can become resistant to treatment, significantly reducing survival rates. Early detection through this test allows for timely intervention, improving prognosis and quality of life.

### How to Prepare for the Test
Preparation for the BCR / ABL – Complete Molecular Genetic Analysis is straightforward. No fasting or special dietary restrictions are required. However, it is important to inform your healthcare provider about any medications or supplements you are taking, as these may influence test results. Follow any specific instructions provided by your doctor or testing facility.

### Test Overview
– **Sample Type**: Whole Blood
– **Methodology**: Real-time PCR (Polymerase Chain Reaction)
– **Turnaround Time (TAT)**: 14 Days

This test uses advanced real-time PCR technology to detect and quantify the BCR-ABL fusion gene with high sensitivity and accuracy. Results are typically available within 14 days, providing critical information for diagnosis and treatment planning.

### Call to Action
Take control of your health today with the BCR / ABL – Complete Molecular Genetic Analysis. Whether you’re seeking a definitive diagnosis or monitoring your treatment progress, this test offers the precision and reliability you need. Don’t wait—book your lab test online now and find a diagnostic test near you to ensure timely and effective care.

**Category**: Molecular